VMT01 Earns FDA Fast Track Designation in MC1R-Positive Melanoma
Source: Targeted Oncology, September 2024
The novel agent VMT01 is designed to target and deliver 212Pb to MC1R-expressing tumors like metastatic melanoma.
- The FDA has granted fast track designation to 212Pb VMT01 for the diagnosis and treatment of unresectable or metastatic melanoma with MC1R tumor expression.
- VMT01 is being investigated in a phase 1/2 study (NCT05655312).
- The agent is designed to target and deliver 212Pb to tumor sites expressing MC1R.
VMT01 has been granted a fast track designation from the FDA for the treatment of MC1R-expressing unresectable or metastatic melanoma.